[go: up one dir, main page]

WO1994027594A3 - Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives - Google Patents

Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives Download PDF

Info

Publication number
WO1994027594A3
WO1994027594A3 PCT/US1994/006247 US9406247W WO9427594A3 WO 1994027594 A3 WO1994027594 A3 WO 1994027594A3 US 9406247 W US9406247 W US 9406247W WO 9427594 A3 WO9427594 A3 WO 9427594A3
Authority
WO
WIPO (PCT)
Prior art keywords
copper
agents
complexes
stable
stable copper
Prior art date
Application number
PCT/US1994/006247
Other languages
English (en)
Other versions
WO1994027594A2 (fr
Inventor
Alexander J Pallenberg
Andrew Branca
Thomas M Marschner
Leonard M Patt
Original Assignee
Procyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procyte Corp filed Critical Procyte Corp
Priority to EP94919342A priority Critical patent/EP0701439A1/fr
Priority to AU70517/94A priority patent/AU7051794A/en
Priority to JP7501073A priority patent/JPH08511006A/ja
Priority to ZA949336A priority patent/ZA949336B/xx
Publication of WO1994027594A2 publication Critical patent/WO1994027594A2/fr
Publication of WO1994027594A3 publication Critical patent/WO1994027594A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés stables de cuivre(I) et des procédés affins. Les composés stables de cuivre(I) comprennent un ion de cuivre(I) associé à un ligand polydenté qui favorise l'état d'oxydation +1 du cuivre. Les procédés décrits comprennent l'utilisation des composés stables de cuivre(I) comme agents de guérison de blessures, agents antioxydants, agents anti-inflammatoires, modulateurs de lipides, modulateurs de la transduction de signaux, comme agents stimulant la pousse des cheveux et comme agents antiviraux. Des exemples de composés stables de cuivre(I) comprennent la néocupréine de cuivre(I) et l'acide disulfonique de bathocuproïne de cuivre(I).
PCT/US1994/006247 1993-06-02 1994-06-02 Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives WO1994027594A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP94919342A EP0701439A1 (fr) 1993-06-02 1994-06-02 Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives
AU70517/94A AU7051794A (en) 1993-06-02 1994-06-02 Stable copper(1) complexes and methods related thereto
JP7501073A JPH08511006A (ja) 1993-06-02 1994-06-02 安定な銅（▲ｉ▼）錯体及びそれに関する方法
ZA949336A ZA949336B (en) 1994-06-02 1994-11-24 Stable copper (I) complexes and methods related thereto.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02
US08/071,440 1993-06-02

Publications (2)

Publication Number Publication Date
WO1994027594A2 WO1994027594A2 (fr) 1994-12-08
WO1994027594A3 true WO1994027594A3 (fr) 1995-04-27

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006247 WO1994027594A2 (fr) 1993-06-02 1994-06-02 Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives

Country Status (8)

Country Link
EP (1) EP0701439A1 (fr)
JP (1) JPH08511006A (fr)
AU (1) AU7051794A (fr)
CA (1) CA2163640A1 (fr)
OA (1) OA10198A (fr)
TW (1) TW239077B (fr)
WO (1) WO1994027594A2 (fr)
ZA (1) ZA943857B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
WO2005115379A2 (fr) * 2004-05-24 2005-12-08 New York University Methode de traitement ou de prevention d'effets pathologiques d'augmentations aigues de l'hyperglycemie et/ou d'augmentations aigues de flux d'acides gras libres
WO2006135965A1 (fr) * 2005-06-20 2006-12-28 Dynamiclear Pty Ltd Composition pour traiter les lésions cutanées
KR20160112021A (ko) * 2008-09-03 2016-09-27 가부시키가이샤 엔비씨 메슈테크 항바이러스제
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
TWI580787B (zh) * 2012-12-28 2017-05-01 簡宏堅 重組蛋白質、含有該重組蛋白質之醫藥組成物及該重組蛋白質之製備方法
WO2019055490A1 (fr) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Conditionnement de tissu irradié pour rétention de greffe de graisse
WO2019236596A1 (fr) * 2018-06-04 2019-12-12 Chemistryrx. Compositions topiques pour stimuler la pousse des cheveux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIJLOO, G. J. ET AL: "Copper complexes of 1,10-phenanthroline and related compounds as superoxide dismutase mimetics", J. INORG. BIOCHEM., 1990, VOL. 40, PAGE(S) 237-44 *
BROWN DH ET AL: "Antiinflammatory effects of some copper complexes.", J MED CHEM (UNITED STATES), JUL 1980, VOL. 23, NO. 7, PAGE(S) 729-34, *
DATABASE WPI Week 8716, Derwent World Patents Index; AN 87-112954 *
DAVIS P.: "Penicillamine metal chelates and their possible importance in rheumatoid arthritis - A brief review", CLIN. INVEST. MED. (ENGLAND), 1984, VOL. 7, NO. 1, PAGE(S) 41-44, *
GAISSER, H. D. ET AL: "Determination of pKa values of 2,2'-bipyridyl analogs and stability constants of their copper(I) and copper(II) complexes;relationship to antimycoplasmal activity.", EUR. J. MED. CHEM.--CHIM. THER., 1986, VOL. 21, PAGES 285-9 *
SORENSON J.R.J. ET AL: "Antiulcer activities of D-penicillamine copper complexes", AGENTS ACTIONS (SWITZERLAND), 1982, VOL. 12, NO. 3, PAGE(S) 408-411, *

Also Published As

Publication number Publication date
WO1994027594A2 (fr) 1994-12-08
AU7051794A (en) 1994-12-20
EP0701439A1 (fr) 1996-03-20
TW239077B (fr) 1995-01-21
JPH08511006A (ja) 1996-11-19
OA10198A (en) 1996-12-18
CA2163640A1 (fr) 1994-12-08
ZA943857B (en) 1995-02-01

Similar Documents

Publication Publication Date Title
WO1994027594A3 (fr) Complexes stables de cuivre(i) et leur utilisation comme substances therapeutiques actives
CA2234282A1 (fr) Complexes medicament/resine stabilises par des chelateurs
AU7497391A (en) Preparation of n-phosphonomethylglycin by oxidation of n-phosphonomethyliminodiacetic acid
AU1874995A (en) Improved color stability of dental compositions containing metal complexed ascorbic acid
TR199902324A3 (tr) Az çözünen bilesiklerin kararli kompleksleri.
EP0992501A3 (fr) Dérivés d'acide pyridonecarboxylique en tant qu'agent antibactérien
AU5162796A (en) Novel peptide derivatives
AU2054097A (en) Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
IL132107A0 (en) Substituted phenyl derivatives their preparation and use
HRP20000381B1 (en) Stable complexes of poorly soluble compounds
EP0823993A3 (fr) Microcapsules sensibles au PH.
AU9097791A (en) Phosphonic acid derivatives useful as antiinflammatory agents
AU1064988A (en) Polymer complexes of metals useful as pharmaceutical agents
AU648315B2 (en) The use of macrocyclic aminophosphonic acid complexes as imaging agents
EP0341607A3 (fr) Peptides alcools anticoagulants
CA2170645A1 (fr) Procede de preparation du n-methyl-3-(1-methyl-4-piperidinyl)-14-indole-5-ethanesulfonamide
AU6274896A (en) Stable copper(i) complexes as active therapeutic substances
DE69103788D1 (de) Verfahren zur Herstellung von Zyklopentadienylkarbonylkomplexen von Übergangsmetallen.
ZA975755B (en) Useful formulations of acid addition salt drugs.
WO1997035568A3 (fr) Composes d'inclusions gamma/cyclodextrine du diclofenac
FR2619676B3 (fr) Pulverisateur, notamment pour l'agriculture
AU2158799A (en) Polyrotaxanes
FR2703880B1 (fr) Utilisation de dérivés de l'acide 7-éthynyl alpha-(méthoxy-méthylène) 1-naphtalène acétique pour la préparation de compositions fongicides.
SG50542A1 (en) Bis (pnenyl) ethane derivatives
AU5635496A (en) Derivatives of 2,3:4,6-di-o-isopropylidene-alpha-l-xylo-2-he xulofluranosonic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2163640

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 267860

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994919342

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994919342

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994919342

Country of ref document: EP